GeneCentric Therapeutics teams up with Labcorp

By staff writers

October 12, 2021 -- GeneCentric Therapeutics has formed a strategic partnership with Labcorp to develop and commercialize RNA-based gene signatures for oncology diagnostics.

Building upon their existing relationship, GeneCentric and Labcorp Drug Development will co-develop the RNA-based gene signatures, with subsequent tests being deployed to major academic and community cancer centers through Labcorp Diagnostics, according to GeneCentric.

LabCorps's deidentified clinical and genomic data -- along with GeneCentric's pharmaceutical and biotechnology partnerships -- will be used to develop the gene signatures and associated diagnostics.

Under the deal, GeneCentric will earn development milestones in addition to commercialization terms. Labcorp has also completed an upfront investment in the company.

Labcorp acquires women's digital health firm Ovia
Labcorp announced it has acquired digital health firm Ovia Health in a move the company said aims to improve patient experience and reduce healthcare...
Labcorp deploys new SARS-CoV-2 sequencing panel
Labcorp will start using Molecular Loop Biosciences' SARS-CoV-2 research sequencing panel to sequence thousands of complete coronavirus genomes each week...
OmniSeq, Labcorp launch new oncology test
OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and...
Labcorp to buy intellectual property from Myriad Genetics
Labcorp plans to buy some of Myriad Genetics' operating assets and intellectual property from its autoimmune business unit, including its Vectra rheumatoid...
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict...

Copyright © 2021

Last Updated np 10/19/2021 8:58:42 AM